Literature DB >> 30426626

Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: A systematic review and meta-analysis.

Yael Barer1, Ohad Cohen1,2, Tali Cukierman-Yaffe1,2,3,4.   

Abstract

The role of intensive glucose control in people with type 2 diabetes and pre-existing cardiovascular disease (CVD) is controversial. The aim of this systematic review and meta-analysis was to determine in a subset of people with type 2 diabetes and pre-existing CVD, the CV effect of intensive glucose control versus standard of care. We searched Medline, the Cochrane library, EMBASE and the National Institutes of Health Trial registration database for randomized controlled trials that evaluated the effect of intensive glucose control versus standard glucose control in people with type 2 diabetes on incident CVD. Data were extracted using a structured form. When data were not available in the publications, authors were contacted. Eight trials involving 8339 participants were included. Among adults with type 2 diabetes and pre-existing CVD, there was no difference in the risk of CV events in those allocated to intensive glucose control compared with those in the standard care arm (relative risk 0.98, 95% confidence interval 0.87-1.09). In conclusion, in people with diabetes and pre-existing CVD, intensive glucose control versus standard care had a neutral effect on incident CV events.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiovascular disease; glucose control; intensive; meta-analysis; systematic review; type 2 diabetes

Year:  2018        PMID: 30426626     DOI: 10.1111/dom.13581

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  5 in total

1.  Predictive Capacity of Beat-to-Beat Blood Pressure Variability for Cardioautonomic and Vascular Dysfunction in Early Metabolic Challenge.

Authors:  Souha A Fares; Nour-Mounira Z Bakkar; Ahmed F El-Yazbi
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

2.  Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials.

Authors:  Dario Giugliano; Maria Ida Maiorino; Giuseppe Bellastella; Paolo Chiodini; Katherine Esposito
Journal:  J Am Heart Assoc       Date:  2019-06-05       Impact factor: 5.501

3.  The residual cardiorenal risk in type 2 diabetes.

Authors:  Dario Giugliano; Maria Ida Maiorino; Giuseppe Bellastella; Katherine Esposito
Journal:  Cardiovasc Diabetol       Date:  2021-02-05       Impact factor: 9.951

Review 4.  Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.

Authors:  Dario Giugliano; Miriam Longo; Lorenzo Scappaticcio; Paola Caruso; Katherine Esposito
Journal:  Cardiovasc Diabetol       Date:  2021-01-11       Impact factor: 9.951

5.  Association of type 2 diabetes remission and risk of cardiovascular disease in pre-defined subgroups.

Authors:  Hilda Hounkpatin; Beth Stuart; Andrew Farmer; Hajira Dambha-Miller
Journal:  Endocrinol Diabetes Metab       Date:  2021-06-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.